Evidence map›Paper›PMID 40488895›Full record

ReviewRheumatology international2025

Late-onset rheumatoid arthritis: clinical features, diagnostic challenges, and treatment approaches.

Olena Zimba, Chokan Baimukhamedov, Burhan Fatih Kocyigit

Abstract readReview
In one paragraph

Review in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Reply.Arthritis & rheumatology (Hoboken, N.J.) · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Clinical and Sonographic Pattern of Late-Onset and Early-Onset Rheumatoid Arthritis: Comparative Study.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2026
    Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Olena ZimbaDepartment of Rheumatology, Immunology and Internal Medicine, University Hospital in Krakow, Krakow, Poland.ORCID http://orcid.org/0000-0002-4188-8486
Chokan BaimukhamedovSouth Kazakhstan Medical Academy, Shymkent, Kazakhstan.ORCID http://orcid.org/0000-0003-3261-1036
Burhan Fatih KocyigitDepartment of Physical Medicine and Rehabilitation, University of Health Sciences, Adana City Research and Training Hospital, Adana, Türkiye. bfk2701@hotmail.com.ORCID http://orcid.org/0000-0002-6065-8002

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Late-Onset Rheumatoid Arthritis (LORA) is receiving increased clinical attention due to global aging trends. LORA presents distinct diagnostic, clinical, and therapeutic challenges. It often presents with a balanced gender distribution, acute onset, preferential involvement of larger joints, and decreased seropositivity. The diagnostic process is complex due to atypical presentations, comorbidities, and limitations of classification criteria, which insufficiently address the heterogeneity of LORA phenotypes. Patients with LORA often experience age-related geriatric syndromes, including frailty, cognitive decline, and malnutrition, in addition to comorbid cardiovascular disorders, pulmonary involvement, oncologic conditions, and osteoporosis. All these factors confound disease progression and treatment strategies, necessitating careful consideration of polypharmacy and modified drug metabolism. While the treatment principles largely align with those of Younge-Onset Rheumatoid Arthiritis (YORA), LORA management requires individualized approaches. Available evidence suggests that with proper monitoring, disease-modifying anti-rheumatic drugs (DMARDs) are safe and effective for older adults. Glucocorticoids should be minimized due to potential detrimental effects. Despite elevated baseline disease activity and functional deterioration, effectively managed LORA patients may achieve disease control similar to that of younger individuals. This review advocates for age-adjusted diagnostic strategies and patient-centered care models tailored to the needs of older RA patients. Addressing these unmet needs may enhance outcomes and quality of life for the growing population of LORA patients.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidAgedAge FactorsAge of OnsetComorbidityDisease ProgressionFemaleHumansMaleAntirheumatic AgentsAgedComorbidityGeriatricsLate-onset rheumatoid arthritisRheumatoid arthritis

Identifiers

PMID40488895
PMCPMC12149268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.